TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes
The Taiwanese company TWi Biotechnology is having some success with an oral small-molecule IL-1beta inhibitor in the treatment of type 2 diabetes, Phase IIb data suggest. The product is the leading small molecule acting on this target being.....
Original Article: TWi Biotechnology sees hints of success in anti-inflammatory approach to type 2 diabetes
NEXT ARTICLE